Breaking News Instant updates and real-time market news.

AKAM

Akamai

$57.76

1 (1.76%)

, AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

17:33
12/15/17
12/15
17:33
12/15/17
17:33

On The Fly: After Hours Movers

HIGHER: Akamai (AKAM), up 13.9% after Elliott reported a 6.5% stake in the company... TD Ameritrade (AMTD), up 2.3% after CNBC reported that the company plans to offer bitcoin futures... Procter & Gamble (PG), up 1.1% after it named Trian's Nelson Peltz to its board of directors. LOWER: Aratana Therapeutics (PETX), down 10.1% after its AT-016 pivotal study did not achieve protocol-defined efficacy success criteria... HP Enterprise (HPE), down 0.8% after it filed an automatic mixed securities shelf.

AKAM

Akamai

$57.76

1 (1.76%)

AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

PG

Procter & Gamble

$91.89

0.89 (0.98%)

PETX

Aratana Therapeutics

$5.73

0.15 (2.69%)

HPE

HP Enterprise

$14.41

0.17 (1.19%)

  • 09

    Jan

  • 13

    Dec

AKAM Akamai
$57.76

1 (1.76%)

10/25/17
RHCO
10/25/17
NO CHANGE
Target $57
RHCO
Hold
Akamai price target raised to $57 from $51 at SunTrust
SunTrust analyst Greg Miller raised his price target on Akamai after stronger than expected Q3 earnings driven by Media performance. The analyst maintains a Hold rating on Akamai due to weak results in the larger Performance/Security business however, noting that the Media business may be volatile.
11/13/17
DADA
11/13/17
NO CHANGE
Target $7
DADA
Buy
Limelight Networks geared for larger content than Akamai, says DA Davidson
DA Davidson analyst Mark Kelleher compares the networking technology at Limelight Networks (LLNW) versus that of Akamai (AKAM), saying that because Limelight is more centrally organized across its 84 data centers, it can deliver information with less internet congestion. Kelleher notes that he recently discussed the contrast with Limelight CFO Sajid Malhotra, who explained that customers are willing to pay more for this type of content delivery relative to Akamai, which places its Content Delivery Network within the data centers of its ISP partners. While Akamai's CDN is more advantageous for smaller content like web pages, Kelleher says the rapid growth in video is quickly creating congestion problems for its network. The analyst has a Buy rating on Limelight Networks, nudging his price target to $7 from $6 based on the company's return to top-line growth, as well as improved operating margins, cash flow, and positive earnings.
11/30/17
MKMP
11/30/17
NO CHANGE
Target $65
MKMP
Buy
Akamai price target raised to $65 from $58 at MKM Partners
MKM Partners analyst Rob Sanderson raised his price target on Akamai to $65, modeling 2019 expectations of return to growth for its Media segment and a 23% growth in its Cloud Security business due to a strong revenue ramp from Enterprise Security products. Sanderson keeps his Buy rating on Akamai, adding that management may also discontinue the product segment disclosure in the near future while focusing on the customer segmentation going forward.
12/04/17
PIPR
12/04/17
NO CHANGE
Target $59
PIPR
Overweight
Akamai Q4 tracking at or above guidance midpoint, says Piper Jaffray
E-commerce spending is a significant driver for Akamai in Q4 and according to Adobe, U.S. spending grew 18% year-over-year for Thanksgiving, Black Friday and Cyber Monday, Piper Jaffray analyst Michael Olson tells investors in a research note. He believes the "strong start" to the holiday buying period suggests Akamai's Q4 is tracking at or above the midpoint of its $638M-$656M revenue guidance range. The consensus is currently at $648M. Olson keeps an Overweight rating on Akamai and trimmed his price target for the shares to $59 from $60 citing the impact of currency and continued conservatism around ongoing investment in the business.
AMTD TD Ameritrade
$51.98

1.1 (2.16%)

11/13/17
11/13/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. J.M. Smucker (SJM) upgraded to Positive from Neutral at Susquehanna with analyst Pablo Zuanic saying he believes the rout of food stocks is ebbing and since this company is the worst performing stock in his coverage universe, he chose to play the food trade with it. 2. Delek US (DK) upgraded to Strong Buy from Outperform at Raymond James with analyst Justin Jenkins saying it will benefit from a wider Brent-WTI spread. 3. Nvidia (NVDA) upgraded to Market Perform from Underperform at BMO Capital with analyst Ambrish Srivastava saying the company has demonstrated a "far stronger" data center business than he had forecast and its leverage is greater than anticipated. 4. Praxair (PX) upgraded to Buy from Hold at Argus with analyst Bill Selesky saying the company is well positioned to deliver stronger Earnings Per Share growth thanks to its mix of high-growth businesses driving above-industry-average margins, earnings, and returns on invested capital. 5. TD Ameritrade (AMTD) upgraded to Buy from Hold at Deutsche Bank with analyst Brian Bedell saying trading volumes are improving, trade pricing will hold up better than expected and the Scottrade integration is going very well. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/17
FBCO
11/30/17
INITIATION
Target $45
FBCO
Underperform
TD Ameritrade initiated with an Underperform at Credit Suisse
Credit Suisse analyst Craig Siegenthaler started TD Ameritrade with an Underperform rating and $45 price target. The analyst believes the company's "lower quality" revenue sources and continued business mix shift are risks.
12/07/17
MSCO
12/07/17
NO CHANGE
MSCO
Morgan Stanley says TD Ameritrade most likely discount broker to embrace bitcoin
Given recent regulatory approval and the upcoming launch of bitcoin futures trading on CME (CME) and CBOE (CBOE), Morgan Stanley analyst Michael Cyprys said he expects discount brokers including E-Trade (ETFC), TD Ameritrade (AMTD) and Ally Financial (ALLY) to offer bitcoin futures trading within the next few months. Among them, he views TD Ameritrade as most likely to embrace bitcoin and lead the way and Charles Schwab (SCHW) as likely to be a latecomer. Cyprys added that he was surprised, given its status as a "challenger brand," that E-Trade has said it will take "a wait-and-see" approach.
12/13/17
RHCO
12/13/17
NO CHANGE
Target $60
RHCO
Buy
TD Ameritrade monthly metrics tracking to meet or top Q1 forecast, says SunTrust
SunTrust analyst Douglas Mewhirter kept his Buy rating and $60 price target on TD Ameritrade after the company released its November monthly metrics. Mewhirter says that daily average revenue trades - DARTs - of 759k were up from last month's 680k and also grew on the year from 540k. Likewise, the client asset growth of 2% to $1.16B likely reflects the market appreciation, says the analyst. Mewhirter raises his FY18 EPS view by 2c to $2.42 and FY19 EPS view by 7c to $3.07.
PG Procter & Gamble
$91.89

0.89 (0.98%)

11/16/17
JEFF
11/16/17
NO CHANGE
Target $99
JEFF
Buy
Jefferies says P&G 'win-win' thesis intact after Peltz victory
Jefferies analyst Kevin Grundy sees Procter & Gamble shares trading up on news of Nelson Peltz claiming a narrow victory following a proxy recount. The analyst says the development fortifies his "win-win" thesis. Either P&G delivers financial results at least in-line with Street expectations or Peltz likely pushes for greater changes at the company, Gruny tells investors in a research note. He reiterates a Buy rating on Procter & Gamble with a $99 price target.
12/13/17
DBAB
12/13/17
INITIATION
Target $101
DBAB
Buy
Procter & Gamble initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Steve Powers started Procter & Gamble with a Buy rating and $101 price target. The company is well positioned after "finally" catching up with market realities," the analyst contends. He views the risk/reward as attractive at current share levels.
10/18/17
JEFF
10/18/17
NO CHANGE
Target $104
JEFF
Buy
Jefferies likes setup for Procter & Gamble into Q1 results
Jefferies analyst Kevin Grundy says he likes the setup for Procter & Gamble into the company's Q1 earnings report on October 20. Expectations are low for the quarter, and the company has incentive to deliver strong results amid activist pressure from Trian, Grundy tells investors in a pre-earnings research note. He reiterates a Buy rating on Procter with a $104 price target.
10/20/17
STFL
10/20/17
UPGRADE
Target $87
STFL
Buy
Procter & Gamble price target lowered to $87 from $90 at Stifel
Stifel analyst Mark Astrachan called Procter & Gamble's EPS beat "lower quality," noting that the company continues to grow sales below global category growth and that pre-tax income excluding corporate costs declined 3%. Following the report, he kept his FY18 and FY19 EPS estimates largely unchanged, but lowered his price target on P&G shares to $87 from $90 to reflect a lower multiple given the company's weakened fundamentals. Astrachan keeps a Hold rating on the stock.
PETX Aratana Therapeutics
$5.73

0.15 (2.69%)

02/06/17
STFL
02/06/17
DOWNGRADE
STFL
Hold
Aratana Therapeutics downgraded to Hold from Buy at Stifel
11/17/17
HCWC
11/17/17
INITIATION
Target $10
HCWC
Buy
Aratana Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Aratana Therapeutics with a Buy rating and $10 price target. The analyst views animal health as a growing market that is "ready for a revolution." He believes the company is well positioned to lead the change in animal health and offers an attractive option for biotech investors.
04/13/17
JEFF
04/13/17
NO CHANGE
Target $8
JEFF
Buy
Zoetis deal for Nexvet suggests $9 per share value for Aratana, says Jefferies
After Zoetis (ZTS) announced a deal to buy Nexvet Biopharma for $85M, Jefferies analyst David Gu said the multiple for the deal would suggest a $9 per share valuation for Aratana Therapeutics (PETX), which is also innovative companion animal biotech company. The analyst, who thinks Aratana's Entyce and Nocita would complement the portfolios of an acquirer, keeps a Buy rating and $8 price target on Aratana shares.
HPE HP Enterprise
$14.41

0.17 (1.19%)

12/05/17
OPCO
12/05/17
NO CHANGE
OPCO
Red Hat, VMware 'most important' to future architectures, says Oppenheimer
Oppenheimer analyst Ittai Kidron notes that he attended Amazon Web Services' re:Invent user conference where he conducted a user survey regarding future adoption of public cloud services. The analyst points out that according to the survey, long-term IT architecture plans are tilted heavily toward the public cloud as opposed to a more balanced hybrid cloud approach, the next three years are likely to be a key inflection point for data and applications transfer to the public cloud, and on-premise IT infrastructure vendors are likely to face pressures as the move to public cloud occurs. Within his coverage, users pointed to Red Hat (RHT)/VMware (VMW) as most important to future architectures, with Cisco (CSCO) making progress. Meanwhile, Citrix (CTXS)/HP Enterprise (HPE)/IBM(IBM)/NetApp (NTAP) seem most challenged, Kidron adds.
11/22/17
BOFA
11/22/17
NO CHANGE
Target $12
BOFA
Underperform
HP Enterprise risks skewed to the downside, says BofA/Merrill
BofA/Merrill analyst Wamsi Mohan said the likelihood of large strategic changes occurring following news Meg Whitman is stepping down as CEO is unlikely. Mohan thinks HPE's story has become dependent on a large restructuring and execution and believes risks are skewed to the downside with increased execution risk, lack of positive catalysts, and downside estimate revisions. The analyst reiterates his Underperform rating and trimmed his price target on HP Enterprise to $12 from $13.
11/22/17
BERN
11/22/17
NO CHANGE
Target $18
BERN
Outperform
HP Enterprise CEO departure not entirely surprising, says Bernstein
Bernstein analyst A.M. Sacconaghi, Jr notes that HP Enterprise's Q4 results were modestly disappointing, 2018 was even more notably front end loaded than he had feared, and CEO Meg Whitman announced that she was stepping down effective February 1. While not entirely surprising, the timing felt abrupt in the context of her recent pronouncements that there "was still work to do" and "I am not going anywhere," Sacconaghi argues. The analyst reiterates an Outperform rating and $18 price target on the shares.
11/22/17
UBSW
11/22/17
NO CHANGE
Target $15
UBSW
Neutral
Whitman departure a marketing negative for HP Enterprise, says UBS
UBS analyst Steven Milunovich noted HP Enterprise (HPE) reported a slight beat for Q4 despite fundamentals remaining mixed. The analyst believes CEO Meg Whitman's departure is a marketing negative and that Dell and Cisco (CSCO) are better positioned to serve on-premises computing needs. He also noted 2018 earnings will be back-end loaded and the stock appears fairly valued while lacking a catalyst. Milunovich maintained his Neutral rating and $15 price target on HP Enterprise shares.

TODAY'S FREE FLY STORIES

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.